Eisai and Biogen report 76% lower dementia progression hazard with LEQEMBI in the three-year LEADER real-world study, alongside persistence, amyloid clearance and SC maintenance findings.
Written By: Neha Vishwakarma, PharmD
Reviewed By: Pharmacally Editorial Team
Eisai and Biogen have reported three-year real-world findings from the Lecanemab in Early Alzheimer’s Disease (LEADER) study, showing a 76% lower hazard of progression to moderate or severe Alzheimer’s disease (AD) dementia among LEQEMBI-treated patients compared with an external natural history cohort. The analysis included 560 patients across 13 US clinical sites and was presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston on November 18, 2026.
The companies also presented a separate international real-world meta-analysis involving approximately 5,000 patients, reporting lower amyloid-related imaging abnormality (ARIA) rates than those observed in the pivotal Clarity AD trial.
About LEQEMBI (Lecanemab)
Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting aggregated soluble amyloid-beta (Aβ) protofibrils and insoluble amyloid-beta forms. Developed through a research alliance between Eisai and BioArctic, it has received approval in 53 countries and regions. Eisai leads global development and regulatory submissions, while Eisai and Biogen jointly commercialize and co-promote the treatment.
Following an initial 18-month treatment period with intravenous (IV) dosing every two weeks, IV maintenance dosing every four weeks has been approved in nine countries. The US Food and Drug Administration (FDA) approved subcutaneous (SC) maintenance dosing with LEQEMBI IQLIK (360 mg) in August 2025 and SC initiation dosing (500 mg) in July 2026.
LEADER Study Design
LEADER is an ongoing multicentre, retrospective real-world study evaluating LEQEMBI utilization, treatment persistence, transition to maintenance therapy, safety and clinical outcomes across diverse US clinical settings. It integrates deidentified medical records from 13 clinical sites with healthcare professional surveys and interviews.
The updated analysis included 560 patients with early AD who had received at least seven initiation infusions as of September 2026. The progression analysis compared 504 LEADER patients with 573 patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), using a weighted external natural history cohort. The maintenance analysis included patients who completed 18 months of biweekly IV treatment and received at least three months of IV or SC maintenance therapy.
Key Clinical Findings
Progression to moderate or severe dementia: In the prespecified 36-month comparison, LEQEMBI-treated patients had a 76% lower hazard of progression to moderate or severe AD dementia than the ADNI-weighted external control cohort (HR 0.24; 95% CI, 0.15–0.39). This represents a relative reduction in progression hazard rather than a 76-percentage-point reduction in absolute risk.
Disease-stage stability: Among 546 patients assessed after an average of approximately 18 months of treatment, 81.1% remained stable (75.8%) or improved (5.3%) compared with baseline. Stability meant remaining in the same clinical stage, while improvement represented a transition from mild AD dementia to mild cognitive impairment (MCI) due to AD. Statistical modelling estimated that 95.0% of the overall 560-patient cohort would remain in early AD through 36 months.
Treatment persistence and amyloid clearance: Overall, 87.5% of patients remained on treatment at chart extraction, with an average treatment duration of approximately 19 months. Among patients reaching 18 months, 91.7% remained on LEQEMBI. At six sites with baseline and follow-up amyloid PET assessments, 33 of 43 patients (77%) became amyloid-negative at a median follow-up of 18.1 months.
IV and SC maintenance: A total of 218 patients transitioned to IV maintenance every four weeks, while 64 received weekly SC maintenance. Disease-stage stability was reported in 71.1% of the IV group and 76.6% of the SC group after average periods of 26 and 25.1 months from treatment initiation, respectively. All 64 SC patients remained on treatment at chart extraction, with no reported ARIA events during SC maintenance. Isolated ARIA-H occurred in 0.5% during IV maintenance.
Safety and international real-world evidence: ARIA-E occurred in 6.6% and ARIA-H in 11.1% of LEADER patients, compared with 6.3% and 10.1%, respectively, in the ALZ-NET registry, which included more than 1,700 LEQEMBI-treated patients.
Separately, a post hoc exploratory meta-analysis of 16 real-world cohorts across six countries, involving approximately 5,000 patients treated for at least six months, reported pooled rates of 12.4% for total ARIA, 4.0% for ARIA-E, 9.4% for ARIA-H and 0.8% for symptomatic ARIA. Discontinuation due to adverse events was 3.2%. These rates were lower than those reported in Clarity AD, although the comparison involved different study populations and monitoring settings.
Clinical Interpretation
These findings extend lecanemab’s evidence base into routine clinical practice, supporting sustained treatment persistence, amyloid clearance and early real-world experience with weekly SC maintenance. They also align directionally with separate five-year Clarity AD long-term extension data presented at CTAD 2026, which showed a 49% lower relative risk of progression to moderate or severe AD dementia versus ADNI and CDR-SB improvement in 62% of patients with low baseline tau. However, differences in study designs and outcome assessments preclude direct cross-trial validation.
Key methodological caveats apply. Because LEADER is retrospective and relies on an external ADNI comparator rather than a randomized control group, residual confounding from patient selection and clinical assessment practices cannot be excluded. Furthermore, the 95.0% three-year stability figure is model-based, while the small subgroups evaluated for amyloid PET (43 patients) and SC maintenance (64 patients) prevent definitive conclusions about comparative efficacy or safety. Prospective controlled studies remain necessary to confirm long-term durability and characterize outcomes across different care settings.
References
New Three-Year Real-World LEQEMBI Data Presented at CTAD 2026, Eisai, November 18, 2026.
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026, Biogen, 18 November 2026
About the Writer
Neha Vishwakarma (LinkedIn) is a Pharm.D professional with experience in clinical pharmacy, pharmacovigilance, and clinical research. She has hands-on experience in ADR assessment, ICSR processing, medication safety, and clinical data evaluation. Her research background in surgical site infections and antibiotic use supports her focus on evidence-based healthcare writing.
